




PROFICIENCY TESTING REPORT

ISHTM-AIIMS EXTERNAL QUALITY ASSURANCE PROGRAMME





Duration of stability testing - minimum upto 8 days at ambient temp. after dispatch of specimens

EQAP CODE No.: 5663 **Distribution No.:** 159-N Month/Year: April/2023

Instrument ID: BC 5150

Name & Contact No. of PT Co-ordinator: Dr. Seema Tyagi (Prof.), Hematology, AIIMS, Delhi,

Tel: 9013085730, E-Mail: accuracy2000@gmail.com Date of issue & status of the report: 14-06-2023[Final].

CBC and Retic Assessment

				Among Lab (Accuracy Testing)				Within Lab (Precision Testing)				
Test Parameters	S.No.	Your Result 1		Your Results Sum of 2 Value	Consensus result sum of 2 values (Assigned Value)	Uncertainty		Results		Uncertainty of Assigned Values	Z Score	
WBC x10³/μl	1	3.87	3.83	7.7	8.1	0.039	-0.34	0.04	0.1	0.007	-0.48	
RBC x10 ⁶ /μl	1	5.48	5.45	10.93	10.7	0.013	0.62	0.03	0.05	0.003	-0.34	
Hb g/dl	1	12.7	12.5	25.2	25.2	0.026	0.00	0.2	0.1	0.007	0.67	
НСТ%	1	42.5	42.5	85	79.8	0.155	1.11	0	0.4	0.025	-0.90	
MCV-fl	1	78.1	77.4	155.5	149.4	0.206	0.96	0.7	0.2	0.017	1.69	
MCH-Pg	1	23.2	22.7	45.9	46.8	0.059	-0.56	0.5	0.2	0.012	2.02	
MCHC-g/dl	1	29.8	29.4	59.2	62.5	0.120	-0.88	0.4	0.3	0.018	0.34	
Plt. x10³/μl	1	206	173	379	371	1.599	0.17	33	7	0.392	3.90	
Retic %	2	20	18	38	15.65	0.249	2.93	2	0.5	0.034	2.53	

P.S. Assesment

		YOUR REPORT	CONSENSUS REPORT				
DLC%	3		Poly: 44 - 60, Myelo: 10 - 22, Meta: 7- 16, Lympho: 2- 6, Promyelo: 2-6, Eosino: 1-4, Blast: 1-4, Mono: 1 - 3, nRBC/Baso: 0-5				
RBC Morphology	3		Predominantly: Normocytic/Normochromic; Moderate: Anisocytosis, hypochromia, Microcytosis; Mild: Macrocytosis, Poikilocytosis				
Diagnosis	3	chronic myeloid leukemia	Chronic Myeloid Leukemia (Chronic Phase)				

COMBINED DATA VALUES OF TOTAL PARTICIPANTS

Test parameters	S.No.	Total participants	Total No. responded	% of Labs with Z Score 0-2		% of Labs with Z Score 2-3		% of Labs with Z Score >3		
rest parameters		current dist. 159N		Among labs	Within lab	Among labs	Within lab	Among labs	Within lab	
WBC x10³/μl	1	363	358	88.55	86.31	3.07	6.42	8.38	7.27	
RBC x10 ⁶ /μl	1	363	363	87.6	87.05	6.89	4.96	5.51	7.99	
Hb g/dl	1	363	363	90.63	85.12	4.96	5.23	4.41	9.65	
HCT%	1	363	3 <mark>59</mark>	94.71	87.47	4.46	4.74	0.83	7.79	
MCV-fl	1	363	359	93.04	88.3	5.29	6.69	1.67	5.01	
MCH-Pg	1	363	359	86.91	<mark>9</mark> 3.31	8.08	1.39	5.01	5.3	
MCHC-g/dl	1	363	358	93.85	87.43	5.31	5.59	0.84	6.98	
Plt. x10³/μl	1	363	359	92.76	92.48	4.74	3.9	2.5	3.62	
ReticCount%	2	363	272	93.38	84.93	4.78	8.82	1.84	6.25	
PS Assessment	3	363	266	Satisfactory:93.95%, Borderline Sat.: 2.20%, Unsatisfactory: 3.85%						

*Comments:

1). Among Lab (EQA): Results acceptable.

2). Within Lab (IQA): Difference in the CBC measurement values for *PLT* unacceptable, may be due to random/human error.

Note-1: EQA (External Quality Assurance): Your Performance among various of participating labs in PT, to determine the accuracy of your results.

IQA (Internal Quality Assurance): Your Performance of comparison of two consecutive measurement values within your lab to test the precision of your autoanalyzer.

Note-2: Z score among & within lab were calculated, as per to ISO/IEC 13528:2015 standard. Z score among lab (EQA)= (Your Result Sum of two values - Consensus Result sum of two values)/(Normalised IQR)

Z score within lab (IQA)= (Your Result Difference of two values – Consensus Result difference of two values)/(Normalised IQR)

IQR = Quartile 3 - Quartile 1 of participant data, Normalised IQR = 0.7413 x IQR

Note-3: Z score 0 to ± 2 : Acceptable, Z score ± 2 to ± 3 : Warning Signal, Z score $> \pm 3$: Unacceptable [As per ISO/IEC 13528:2015 standard]

Note-4: Z score value between "0 to ± 2 " are texted in green colour. Z score value between " ± 2 to ± 3 " are texted in orange colour. Z score value $> \pm 3$ are texted in red colour.

Note-5: Homogeneity and stability testing of PT sample were done as per ISO 13528:2015 standard. To pass homogeneity test, between sample SD (Ss) should be smaller than the check value (0.3*SDPA). To pass the stability test, average difference in measurement values of first and last day sample $(\bar{x}-\bar{y})$ should be smaller than the check value (0.3*SDPA).

Note-6: ISHTM-AIIMS-EQAP does not subcontract any task of its scheme

Note-7: Participants are free to use methods/analyzer of their own choice.

Note-8: Proficiency testing (PT) samples are sent quarterly to each participant.

Note-9: All the necessary details regarding design and implementation of PT, are provided in the instruction sheet as well as on programme's website www.ishtmaiimseqap.com.

Note 10: Reports are kept confidential.

Report authorized by,

Dr. Seema Tyagi (Prof.)

PT Co-ordinator: ISHTM-AIIMS-EQAP

Department of Hematology, AIIMS, New Delhi

-----End Of Report-----